Menu Search
Equities

Pangenomic Health Inc

LL31:STU

Pangenomic Health Inc

Actions
  • Price (EUR)0.051
  • Today's Change-0.012 / -18.40%
  • Shares traded0.00
  • 1 Year change-87.12%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pangenomic Health Inc. is a precision health company. The Company, through its subsidiaries, is engaged in developing a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Its products include a mobile app for consumers (Nara), a telehealth mental health app and telehealth platform for consumers (Mindleap) and a clinical decision support platform for health practitioners (MUJN). The Nara mobile app provides consumers with a knowledge base, which is based on individual's user profile, leveraging input from mental health questionnaires, drug treatment regimen, genomic sequencing analysis, as well as their protein and microbiome biomarker reports. The Mindleap platform provides a variety of tools and resources to help individuals understand and improve their inner wellness. The MUJN clinical decision support platform provides health practitioners with access to the consumer's mobile app data and their diagnostic reports.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-11.78m
  • Incorporated2015
  • Employees--
  • Location
    Pangenomic Health Inc102 3800 Wesbrook MallVANCOUVER V6S 2L9CanadaCAN
  • Phone+1 (778) 743-4642
  • Fax+1 (604) 688-9588
  • Websitehttps://www.pangenomic.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.